The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task

Journal of Neurogenetics

Volumn 25, Issue 4, 2011, Pages 120-126

  Vardigan, Joshua D ^a   Converso, Antonella ^a   Hutson, Pete H ^a   Uslaner, Jason M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Attention; CGMP; Cognition; PDE9

Indexed keywords

DONEPEZIL; NICOTINE; PF 04447943; PHOSPHODIESTERASE; PHOSPHODIESTERASE 9; PHOSPHODIESTERASE INHIBITOR; SCOPOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ATTENTION; ATTENUATION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HYPOTHESIS; MALE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RAT; RODENT; TASK PERFORMANCE;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; MALE; NOOTROPIC AGENTS; PHOSPHODIESTERASE INHIBITORS; PYRAZOLES; PYRIMIDINONES; RATS; RATS, WISTAR; SCOPOLAMINE HYDROBROMIDE;

RATTUS; RODENTIA;

EID: 81555212312     PISSN: 01677063     EISSN: 15635260     Source Type: Journal    
DOI: 10.3109/01677063.2011.630494     Document Type: Article

References (42)

1. Ali, E. H., & Arafa, N. M. (2011). Comparative protective action of curcumin, memantine and diclofenac against scopolamine-induced memory dysfunction. Fitoterapia, 82, 601-608.
2. Andreeva, S. G., Dikkes, P., Epstein, P. M., & Rosenberg, P. A. (2001). Expression of cGMP-specifi c phosphodiesterase 9A mRNA in the rat brain. J Neurosci, 21, 9068-9076.
3. Bentley, P., Driver, J., & Dolan, R. J. (2011). Cholinergic modulation of cognition: Insights from human pharmacological functional neuroimaging. Prog Neurobiol, 94, 360-388.
4. Bonkale, W. L., Winblad, B., Ravid, R., & Cowburn, R. F. (1995). Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer ' s disease. Neurosci Lett, 187, 5-8.
5. Broks, P., Preston, G. C., Traub, M., Poppleton, P., Ward, C., & Stahl, S. M. (1988). Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia, 26, 685-700.
6. Castoldi, A. F., Manzo, L., & Costa, L. G. (1993). Cyclic GMP formation induced by muscarinic receptors is mediated by nitric oxide synthesis in rat cortical primary cultures. Brain Res, 610, 57-61.
7. Chamberlain, S. R., Muller, U., Robbins, T. W., & Sahakian, B. J. (2006). Neuropharmacological modulation of cognition. Curr Opin Neurol, 19, 607-612.
8. Cools, R., & D ' Esposito, M. (2011). Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry, 69, 113-125.
9. Dalley, J. W., Cardinal, R. N., & Robbins, T. W. (2004). Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev, 28, 771-784.
10. de Vente, J. (2004). cGMP: A second messenger for acetylcholine in the brain? Neurochem Int, 45, 799-812.
11. Domek-Lopacinska, K., van de Waarenburg, M., Markerinkvan Ittersum, M., Steinbusch, H. W., & de Vente, J. (2005). Nitric oxide-induced cGMP synthesis in the cholinergic system during the development and aging of the rat brain. Brain Res Dev Brain Res, 158, 72-81.
12. Domek-Lopacinska, K. U., & Strosznajder, J. B. (2010). Cyclic GMP and nitric oxide synthase in aging and Alzheimer ' s disease. Mol Neurobiol, 41, 129-137.
13. Drachman, D. A., & Leavitt, J. (1974). Human memory and the cholinergic system. A relationship to aging? Arch Neurol, 30, 113-121.
14. Fisher, D. A., Smith, J. F., Pillar, J. S., St Denis, S. H., & Cheng, J. B. (1998). Isolation and characterization of PDE9A, a novel human cGMP-specifi c phosphodiesterase. J Biol Chem, 273, 15559-15564.
15. Foldi, N. S., White, R. E., & Schaefer, L. A. (2005). Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer ' s disease. Int J Geriatr Psychiatry, 20, 485-488.
16. Harada, N., Nishiyama, S., Ohba, H., Sato, K., Kakiuchi, T., & Tsukada, H. (2002). Age differences in phosphodiesterase type-IV and its functional response to dopamine D1 receptor modulation in the living brain: a PET study in conscious monkeys. Synapse, 44, 139-145.
17. Hilbig, H., Holler, J., Dinse, H. R., & Bidmon, H. J. (2002). In contrast to neuronal NOS-I, the inducible NOS-II expression in aging brains is modifl ed by enriched environmental conditions. Exp Toxicol Pathol, 53, 427-431.
18. Hutson, P. H., Finger, E. N., Magliaro, B. C., Smith, S. M., Converso, A., & Sanderson, P. E., et al. (2011). The selective phosphodiesterase 9 (PDE9) inhibitor PF- 04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl) pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5- dihydro-4H-pyrazolo[3,4-d] pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology, 61, 665-676.
19. Jesko, H., Chalimoniuk, M., & Strosznajder, J. B. (2003). Activation of constitutive nitric oxide synthase(s) and absence of inducible isoform in aged rat brain. Neurochem Int, 42, 315-322.
20. Karasawa, J., Hashimoto, K., & Chaki, S. (2008). D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive defi cits in a novel object recognition test in rats. Behav Brain Res, 186, 78-83.
21. Lakics, V., Karran, E. H., & Boess, F. G. (2010). Quantitative comparison of phosphodiesterase mRNA distribution inhuman brain and peripheral tissues. Neuropharmacology, 59, 367-374.
22. Levin, E. D., Bushnell, P. J., & Rezvani, A. H. (2011). Attentionmodulating effects of cognitive enhancers. Pharmacol Biochem Behav, 99, 146-154.
23. Liu, P., Smith, P. F., Appleton, I., Darlington, C. L., & Bilkey, D. K. (2005). Hippocampal nitric oxide synthase and arginase and age-associated behavioral defi cits. Hippocampus, 15, 642-655.
24. Mirza, N. R., Peters, D., & Sparks, R. G. (2003). Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev, 9, 159-186.
25. Molchan, S. E., Martinez, R. A., Hill, J. L., Weingartner, H. J., Thompson, K., Vitiello, B., et al. (1992). Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev, 17, 215-226.
26. Pitsikas, N., & Sakellaridis, N. (2007). Memantine and recognition memory: Possible facilitation of its behavioral effects by the nitric oxide (NO) donor molsidomine. Eur J Pharmacol, 571, 174-179.
27. Reneerkens, O. A., Rutten, K., Steinbusch, H. W., Blokland, A., & Prickaerts, J. (2009). Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl), 202, 419-443.
28. Reyes-Irisarri, E., Markerink-Van Ittersum, M., Mengod, G., & de Vente, J. (2007). Expression of the cGMP-specifi c phosphodiesterases 2 and 9 in normal and Alzheimer ' s disease human brains. Eur J Neurosci, 25, 3332-3338.
29. Robbins, T. W. (2002). The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl), 163, 362-380.
30. Rezvani, A. H., & Levin, E. D. (2004). Nicotine-antipsychotic drug interactions and attentional performance in female rats. Eur J Pharmacol, 486, 175-182.
31. Schliebs, R., & Arendt, T. (2006). The signifi cance of the cholinergic system in the brain during aging and in Alzheimer ' s disease. J Neural Transm, 113, 1625-1644.
32. Shimazaki, T., Kaku, A., & Chaki, S. (2010). D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats. Psychopharmacology (Berl), 209, 263-270.
33. Smith, J. W., Gastambide, F., Gilmour, G., Dix, S., Foss, J., Lloyd, K., et al. (2011). A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology (Berl) .
34. Swartz, B. E., & Woody, C. D. (1979). Correlated effects of acetylcholine and cyclic guanosine monophosphate on membrane properties of mammalian neocortical neurons. J Neurobiol, 10, 465-488.
35. Tonnaer, J. A., Cheung, C. L., & De Boer, T. (1991). cGMP formation and phosphoinositide turnover in rat brain slices are mediated by pharmacologically distinct muscarinic acetylcholine receptors. Eur J Pharmacol, 207, 183-188.
36. Vallebuona, F., & Raiteri, M. (1995). Age-related changes in the NMDA receptor/nitric oxide/cGMP pathway in the hippocampus and cerebellum of freely moving rats subjected to transcerebral microdialysis. Eur J Neurosci, 7, 694-701.
37. Van Dam, D., Abramowski, D., Staufenbiel, M., & De Deyn, P. P. (2005). Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive defi cits in the APP23 model. Psychopharmacology (Berl), 180, 177-190.
38. Van der Staay, F. J., Rutten, K., Barfacker, L., Devry, J., Erb, C., Heckroth, H., et al. (2008). The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology, 55, 908-918.
39. Van Staveren, W. C., Steinbusch, H. W., Markerink-Van Ittersum, M., Repaske, D. R., Goy, M. F., Kotera, J., et al. (2003). mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol, 467, 566-580.
40. Williams, G. V., & Castner, S. A. (2006). Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience, 139, 263-276.
41. Wise, L. E., & Lichtman, A. H. (2007). The uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist memantine prolongs spatial memory in a rat delayed radialarm maze memory task. Eur J Pharmacol, 575, 98-102.
42. Yu, W., Juang, S., Lee, J., Liu, T., & Cheng, J. (2000). Decrease of neuronal nitric oxide synthase in the cerebellum of aged rats. Neurosci Lett, 291, 37-40.